- |||||||||| SCD411 (aflibercept biosimilar) / Sam Chun Dang Pharm
Trial completion: A Study to Comparing SCD411 and Eylea (clinicaltrials.gov) - Oct 10, 2023
P3, N=576, Completed,
Active, not recruiting --> Completed
- |||||||||| SCD411 (aflibercept biosimilar) / Sam Chun Dang Pharm
Enrollment closed, Trial completion date, Trial primary completion date: A Study to Comparing SCD411 and Eylea (clinicaltrials.gov) - May 13, 2022
P3, N=576, Active, not recruiting,
Active, not recruiting --> Completed Trial primary completion date: Feb 2022 --> Nov 2021 | Recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Sep 2022
- |||||||||| SCD411 (aflibercept biosimilar) / Sam Chun Dang Pharm
Enrollment open, Trial completion date: A Study to Comparing SCD411 and Eylea (clinicaltrials.gov) - Nov 17, 2020
P3, N=560, Recruiting,
Trial primary completion date: Feb 2022 --> Nov 2021 | Recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Sep 2022 Not yet recruiting --> Recruiting | Trial completion date: Jan 2022 --> Apr 2022
|
